PUBLIC CONTRACT · 2022
Aquisição de RISANCIZUMAB SC 150MG1ML SOL INJ CAN, ao Laboratório Abbvie, para o HFF, para o ano 2022
- Contract value
- €85,964.85
- Signed on
- 11 January 2022
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9322173PUBLISHED SUBJECT
Aquisição de RISANCIZUMAB SC 150MG1ML SOL INJ CAN, ao Laboratório Abbvie, para o HFF, para o ano 2022
Parties involved
- Place of performance
- Portugal, Lisboa, Amadora
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ABBVIE,LDA · Tax ID 510229050
Values and timeline
- Contract price
- €85,964.85
- Procedure base price
- €85,964.85
- Total effective price
- Not reported on Portal BASE
- Publication date
- 23 June 2022
- Award date
- 24 November 2021
- Signing date
- 11 January 2022
- Performance period
- 354 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea iii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5632781
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.